DDInter575 DDInter1763
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Temsirolimus
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is regulated by {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Temsirolimus
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Disopyramide (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)
Disopyramide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Temsirolimus (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Disopyramide (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Disopyramide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Disopyramide (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Temsirolimus (Compound)
Disopyramide (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is regulated by MTOR (Gene) and MTOR (Gene) is bound by Temsirolimus (Compound)